RE:RE:RE:RE:RE:RE:RE:ManipulationFGPStock ... It's interesting that you cherry picked my posts between May 27 and June 22.
You omitted though to show the evolution in the posts, as new information was found and documented. Looks like you never noticed the nuances posted many times since September.
Sad that you never participate in any digging as you would have understood that digging is an on-going process to narrow-down to a more precise picture. You're more into whining. Just like Bungee was. Armchair quarterback ... ;-)
I understand that you're not always up to date, even when things are clearer, after some updates thanks to new information. So your incomprehension regarding the pp, your questioning of the competency of the management, etc ... It was obvious at first sight that you didn't master key information. The problem was you. You didn't followed the evolution.
Again, it's interesting that you cherry picked my posts between May 27 and June 22. My posts were way more clearer after that, from the moment one poster (and it was sadly not you) first raised the possible 450-day of patients #25. That triggered nuances, additional digging and refining .that we posted .. while you were probably snoozing at your cottage ... ;-).
In no way this data on p#25 was avaliable back then in May and June, given that's it's kind of a moving target. It's the MD&A of August 30 that gave us a bit more insights that allowed us to paint a better picture with more precise details.
So in my posts that you cited (those of May 27 - June 22), the perception of BDT "receive" was solely based on the TLT updated presentation of Feb. 7 as we didn't have more data at that time. That was a start. And better than nothing.
I first noticed and raised the nuance in May regarding BDT (Dec. 2022) and AA (commercial revenues advanced by 30 months, from end 2025 to early 2023). You were probably snoozing at your cottage when I made that initial discovery, and again when we kept digging and added more details, trying to secure your overexposure investment in TLT that renders you nervous, as per your recent worries. ... lolll
So over time, especially with the timeline of the 450-day of p#25 (now expected somewhere between end of November and mid-December), I refined my subsequent posts, to make a distinction between applying for BDT designation (at the earliest mid-December) and the obligation of the FDA to response within 60 days of reception of that application to decide whether or not to grant FDA designation to TLT. The only unknown would be to guess when will all papers (exams, etc ...) will be sent by urologists to TLT and then, when TLT forwards them to the FDA (applying for the FDA designation). Then, the 60-days clock starts.
Funny that you skipped the more detailed posts! Maybe you were snoozing, despite all the waving I was sending you since you first started questioning about the pp and why you found it inappropriate. We now know you were not up to date as you avoided the most recent information. Not me.
ScienceFirst - (
9/7/2022 8:38:31 PM)
RE:RE:BreakThrough Designation ("BTD")
Late November to mid-December should be the 450-day of patient #25.
Urologist must submit its report with all the exam and document so they can be included in the "portfolio" that TLT will submit to the FDA.
So it's fair to assume that the CRO has collected all these documents for many patients so far, as they reached their 450-day milestone.
ScienceFirst - (
10/9/2022 11:04:50 AM)
2nd PP: Expected to close around Oct. 14
Closing of the financing is intended to occur on or about October 14, 2022.
It's also been clever that the first pp (closed Sept. 22) was done separately so we can notice that management participated in it and increased its participation in the company, on top of the May 14 warrants conversion. It sends a powerful (and no-brainer) signal, 45% into a pivotal NMIBC Ph. 2, within reach at being able to apply for Breakthrough designation (patient #25 450-days milestone should be by mid-December at the latest), and with more anti-virus insights from the Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC (Canada's only Lab-4 (located in Winnipeg), famoulsy known for having developed the 100% efficacy Ebola vaccine).
ScienceFirst - (
10/24/2022 7:51:10 PM)
Breakthrough designation granting is inevitable
It's pretty obvious that, after Ph. 1b p#5-6 have reached their 2y+ mark of being cancer free back in August 2021 with a single dose, TLT met with the FDA and received guidances about what would be the criterias that would qualify them for the Breakthrough designation. That's why the TLT's corporate presentation was then updated on Feb. 7 2022 (at the time of excellent news on the COVID-19 news from NML's Dr. Kobasa) to include Breakthrough designation application for NMIBC to around Dec. 2022 (projected) and commercial revenues (projected) early 2023 (only Accelerated Approval program can allow for revenues).
You sounds like Bungee. The exact same default of not mastering the basic information and to question the logic of the management! ;-)
ScienceFirst - (9/7/2022 8:38:31 PM)
RE:RE:Break Through Designation ("BTD")
Late November to mid-December should be the 450-day of patient #25.
Urologist must submit its report with all the exam and document so they can be included in the "portfolio" that TLT will submit to the FDA.
So it's fair to assume that the CRO has collected all these documents for many patients so far, as they reached their 450-day milestone.